NCT04433546View on ClinicalTrials.gov

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

PHASE2TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

December 2, 2020

Study Completion Date

December 2, 2020

Conditions
Acute Respiratory Distress SyndromeCoronavirusHypoxic Respiratory FailureHypoxemic Respiratory FailureRespiratory ComplicationRespiratory InsufficiencyCardiac DysfunctionPneumoniaPulmonary EdemaPulmonary InflammationRespiratory FailureCytokine StormCOVID 19SARS-CoV-2Cardiac EventCardiac ComplicationCardiac FailureCardiac Infarct
Interventions
DRUG

Pemziviptadil (PB1046)

Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection

DRUG

Low Dose (10 mg) Control

Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection (10 mg diluted in sodium chloride to match active drug volume)

Trial Locations (4)

20904

Adventist Healthcare White Oak Medical Center, Silver Spring

32207

Baptist Health Research Institute, Jacksonville

34239

Sarasota Memorial Hospital, Sarasota

66160

The University of Kansas Medical Center, Kansas City

Sponsors
All Listed Sponsors
lead

PhaseBio Pharmaceuticals Inc.

INDUSTRY